| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 01/18/2012 | EP2405899A2 Valsartan formulations |
| 01/18/2012 | EP2405895A1 Compositions comprising a fatty acid oil mixture comprising epa and dha in free acid form and a surfactant, and methods and uses thereof |
| 01/18/2012 | EP2405893A1 Oil-based preparation containing antiprotozoal triazines and anthelmintic cyclodepsipeptides |
| 01/18/2012 | EP2405892A1 Pharmaceutical formulation comprising ketoprofen and a polyoxyalkylene ester of a hydroxy fatty acid |
| 01/18/2012 | EP2405890A2 Riluzole aqueous suspensions |
| 01/18/2012 | EP2405773A1 Stigmasterol for the treatment of alzheimer's disease |
| 01/18/2012 | EP2405772A1 Covalent milk protein/isothiocyanate complexes |
| 01/18/2012 | EP2405756A1 Inhibitors of akt activity |
| 01/18/2012 | EP2405755A1 Methods and compositions for the treatment of metabolic and cardiovascular disorders |
| 01/18/2012 | EP2405754A1 Modified release pharmaceutical compositions of buprenorphine |
| 01/18/2012 | EP2405751A1 Sphingosine kinase inhibitor prodrugs |
| 01/18/2012 | EP2405750A1 Combination therapy with thiocolchicine derivatives |
| 01/18/2012 | EP2405748A1 Administration of intravenous ibuprofen |
| 01/18/2012 | EP2405747A1 Compositions and methods for treatment and prevention of cardiovascular disease |
| 01/18/2012 | EP2321306B1 3-cyanopyrrolidinyl-phenyl-oxazolidinones as antibacterial agents |
| 01/18/2012 | EP2320902B1 Pharmaceutical composition comprising lapatinib |
| 01/18/2012 | EP2310395B1 9-substituted-b-carboxy-oxadiazino-quinolone derivatives, their preparation and their application as anti-bacterials |
| 01/18/2012 | EP2300485B1 Pyrrolo-[2, 3-c]-pyridine derivatives as p38 kinase inhibiting agents |
| 01/18/2012 | EP2300472B1 Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof |
| 01/18/2012 | EP2300424B1 Use of indole derivatives as nurr-1 activators for treating parkinson s disease |
| 01/18/2012 | EP2220076B1 Inhibitors of human immunodeficiency virus replication |
| 01/18/2012 | EP2195317B1 2,3-substituted azaindole derivatives for treating viral infections |
| 01/18/2012 | EP1992618B1 Polycyclic cinnamide derivative |
| 01/18/2012 | EP1968991B1 Bis-platinum complexes with antitumor activity |
| 01/18/2012 | EP1951738B1 Further crystalline forms of rostafuroxin |
| 01/18/2012 | EP1941887B1 Metallo-fullerenols and its application in preparation of medicines for inhibiting the growth of tumour |
| 01/18/2012 | EP1919907B9 Heterocyclic compound |
| 01/18/2012 | EP1893196B1 Diarylhydantoin compound |
| 01/18/2012 | EP1877411B1 Diaryl-purine, azapurines and -deazapurines as non-nucleoside reverse transcriptase inhibitors for treatment of hiv |
| 01/18/2012 | EP1831202B1 Pyrrolinidium derivatives as m3 muscarinic receptors |
| 01/18/2012 | EP1827403B1 Compositions for treating surface ocular pathologies |
| 01/18/2012 | EP1826197B1 Aminocarboxylic acid derivative and medicinal use thereof |
| 01/18/2012 | EP1814532B1 Topical application of muscarinic and opioid agents for treatment of tinnitus |
| 01/18/2012 | EP1784173B1 Pharmaceutical composition for preventing and treating metabolic bone diseases containing alpha-arylmethoxyacrylate derivatives |
| 01/18/2012 | EP1778710B1 Tanaproget derivatives, metabolites, and uses thereof |
| 01/18/2012 | EP1776119B1 Tetrahydro-naphthalene derivatives as glucocorticoid receptor modulators |
| 01/18/2012 | EP1750525B1 Physiological cooling compositions |
| 01/18/2012 | EP1718636B1 New compounds useful for the synthesis of s- and r-omeprazole and a process for their preparation |
| 01/18/2012 | EP1718313B1 Synergistic anti-inflammatory pharmaceutical composition for use in reducing pge2-mediated inflammation |
| 01/18/2012 | EP1713780B1 Novel inhibitors of glutaminyl cyclase |
| 01/18/2012 | EP1713471B1 Combination of anticholinergics and inhibitors of phosphodiesterase type 4 for the treatment of respiratory diseases |
| 01/18/2012 | EP1637539B1 Pyrazole derivative, drug composition containing the same and production intermediate therefor |
| 01/18/2012 | EP1617873B1 Treatment of multi-drug resistant tumours by a conjugate of mitomycin C |
| 01/18/2012 | EP1575671B1 Nutraceutical compositions comprising epigallocatechin gallate and raspberry ketone |
| 01/18/2012 | EP1546138B1 Raloxifene l-lactate or a hemihydrate thereof, their uses, pharmaceutical compositions and preparation processes |
| 01/18/2012 | EP1513499B1 Ibuprofen suspension |
| 01/18/2012 | EP1506196B1 Pyrazolopyrimidines as sodium channel inhibitors |
| 01/18/2012 | EP1494730B1 Composition for hard tissue augmentation |
| 01/18/2012 | EP1490024B1 Effervescent compositions comprising alendronate |
| 01/18/2012 | EP1486213B1 The use of the total coumarins of cnidium monnieri in preparation of the medicament for treating psoriasis |
| 01/18/2012 | EP1430114B1 Prolactin induced increase in neural stem cell numbers and therapeutical use thereof |
| 01/18/2012 | EP1429844B1 Conjugate of perphenazine and gaba and uses thereof |
| 01/18/2012 | EP1420779B1 Process for isolating phenolic compounds |
| 01/18/2012 | EP1360957B1 Vitamin/mineral complex |
| 01/18/2012 | EP1341528B1 Rapidly disintegrating tablet comprising an acid-labile active ingredient |
| 01/18/2012 | EP1292709B1 Conjugate addition reactions for the controlled delivery of pharmaceutically active compounds |
| 01/18/2012 | EP1256574B1 Nitrogen-containing compounds having kinase inhibitory activity and drugs containing the same |
| 01/18/2012 | EP1013661B1 2'-O,4'-C-methylene bicyclonucleosides |
| 01/18/2012 | DE202011109104U1 Organische Säuren natürlichen Ursprungs Organic acids of natural origin |
| 01/18/2012 | CN1976706B Inhibition of FGFR3 and treatment of multiple myeloma |
| 01/18/2012 | CN1950351B 3- or 4-monosubstituted phenol and thiophenol derivatives useful as h3 ligands |
| 01/18/2012 | CN1903860B Technology of preparing high purity cefotamei sodium by solvent process and its medical use |
| 01/18/2012 | CN102325905A Method for determining sensitivity to irinotecan and use thereof |
| 01/18/2012 | CN102325885A Methods and compositions for diagnosis and treatment of cancer |
| 01/18/2012 | CN102325884A Hypo-immunogenic streptavidin and use thereof |
| 01/18/2012 | CN102325784A TGR5 modulators and method of use thereof |
| 01/18/2012 | CN102325783A Synthesis of purine nucleosides |
| 01/18/2012 | CN102325778A Nalmefene hydrochloride dihydrate |
| 01/18/2012 | CN102325777A (+)-morphinananium n-oxides and processes for their production |
| 01/18/2012 | CN102325776A (+)-morphinanium quaternary salts and processes for their production |
| 01/18/2012 | CN102325775A (+)-6-hydroxy-morphinan or (+)-6-amino-morphinan derivatives |
| 01/18/2012 | CN102325773A Derivatives of 6-cycloamino-2,3-di-pyridinyl-imidazo[1,2-b]-pyridazine, preparation and therapeutic application thereof |
| 01/18/2012 | CN102325771A Imidazo [1, 2 -a] pyridines as jnk modulators |
| 01/18/2012 | CN102325770A Piperidine derivatives useful as orexin antagonists |
| 01/18/2012 | CN102325769A Monocarbams |
| 01/18/2012 | CN102325768A Compounds and methods for the treatment of pain and other diseases |
| 01/18/2012 | CN102325767A 7-phenoxychroman carboxylic acid derivatives |
| 01/18/2012 | CN102325766A Heteroaryl substituted pyridazinone derivatives |
| 01/18/2012 | CN102325765A Novel substituted bicyclic heterocyclic compounds as gamma secretase modulators |
| 01/18/2012 | CN102325764A Pyrimidine indole derivatives for treating cancer |
| 01/18/2012 | CN102325763A Sulfamides as TRPM8 modulators |
| 01/18/2012 | CN102325755A Substituted 5,6-dihydro-6-phenylbenzo[f] isoquinolin-2-amine compounds |
| 01/18/2012 | CN102325754A Cyclic compound having hetero atom |
| 01/18/2012 | CN102325753A Carbazole carboxamide compounds useful as kinase inhibitors |
| 01/18/2012 | CN102325752A Carbazole and carboline kinase inhibitors |
| 01/18/2012 | CN102325750A Sulfonamides as trpm8 modulators |
| 01/18/2012 | CN102325566A Selective histamine h4 receptor antagonists for the treatment of vestibular disorders |
| 01/18/2012 | CN102325550A Combination of photodynamic therapy and anti-VEGF agents in the treatment of unwanted choroidal neovasculature |
| 01/18/2012 | CN102325549A Treatment of cancer with umanized anti-egfr igg1 antibody and irinotecan |
| 01/18/2012 | CN102325543A Novel composition containing n2-(1-oxohexadecyl)-lysyl-valyl-lysine, for treatment of acne rosacea and symptom thereof |
| 01/18/2012 | CN102325535A Extraits de cajanus et glucosamine pour troubles inflammatoires |
| 01/18/2012 | CN102325534A Extended dicer substrate agents and methods for the specific inhibition of gene expression |
| 01/18/2012 | CN102325533A Treatment of vaginal atrophy in women with cardiovascular pathology risk |
| 01/18/2012 | CN102325532A Inhalation of levofloxacin for reducing lung inflammation |
| 01/18/2012 | CN102325531A Compounds and methods of use |
| 01/18/2012 | CN102325530A 5- (2-{ [6- (2, 2-difluoro-2-phenylethoxy) hexyl] amino} -1-hydroxyethyl) -8-hydroxyquinolin-2 (ih)-one for treatment of lung function |
| 01/18/2012 | CN102325529A Sigma(s) receptors ligands with anti-apoptotic and/or pro-apoptotic properties, over cellular mechanisms, exhibiting prototypical cytoprotective and also anticancer activity |
| 01/18/2012 | CN102325528A Activated blood coagulation factor X (FXa) inhibitor |
| 01/18/2012 | CN102325526A Extended-release pharmaceutical formulations |
| 01/18/2012 | CN102325525A Dermaceutical gel made using sodium fusidate & process to make it |